Another recent study demonstrated that HK2 deficiency markedly increased the susceptibility of hepatocellular carcinoma cells to the FDA-approved drug, sorafenib, and also enhanced the inhibitory effects of sorafenib on tumor growth in vivo (17). This evidence concerns the gene HK2 and hepatocellular carcinoma.